Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Technology evaluation: huN901-DM1, ImmunoGen.

Suzanne V Smith¹

¹Australian Nuclear Science and Technology Organisation (ANSTO), Institute of Materials Engineering and Science, Menai, NSW 2234, Australia. svs@ansto.gov.au

Current Opinion in Molecular Therapeutics

|August 27, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The ionic charge of copper-64 complexes conjugated to an engineered antibody affects biodistribution.

Bioconjugate chemistry·2015

Same author

Excitation functions of (nat)Zn(p,x) nuclear reactions with proton beam energy below 18 MeV.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2014

Same author

Production of high specific activity (195m) Pt-cisplatinum at South African Nuclear Energy Corporation for Phase 0 clinical trials in healthy individual subjects.

Journal of labelled compounds & radiopharmaceuticals·2013

Same author

Synthesis of hexa aza cages, SarAr-NCS and AmBaSar and a study of their metal complexation, conjugation to nanomaterials and proteins for application in radioimaging and therapy.

Dalton transactions (Cambridge, England : 2003)·2013

Same author

Optimizing radiolabeling amine-functionalized silica nanoparticles using SarAr-NCS for applications in imaging and radiotherapy.

Langmuir : the ACS journal of surfaces and colloids·2013

Same author

Molecular imaging with copper-64 in the drug discovery and development arena.

Expert opinion on drug discovery·2013

Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011

Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010

Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010

Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010

Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010

Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010

See all related articles

ImmunoGen is developing huN901-DM1, a targeted antibody-drug conjugate for CD56-expressing cancers. This therapy shows potential for treating small-cell lung cancer.

Area of Science:

Oncology
Immunotherapy
Drug Development

Background:

Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options.
CD56 is a cell surface marker expressed on SCLC and other neuroendocrine tumors.
Targeted therapies offer a promising strategy to improve treatment efficacy and reduce systemic toxicity.

Purpose of the Study:

To evaluate the potential of huN901-DM1 as a novel therapeutic agent for CD56-positive cancers.
To investigate the efficacy of huN901-DM1 in preclinical models of small-cell lung cancer.

Main Methods:

huN901-DM1 is an antibody-drug conjugate (ADC) comprising a CD56-targeted humanized N901 antibody linked to the cytotoxic agent DM1.
Utilizes ImmunoGen's proprietary tumor-activated prodrug technology.

Related Experiment Videos

Preclinical studies in relevant cancer models are employed to assess anti-tumor activity.

Main Results:

The huN901-DM1 compound targets CD56-expressing tumor cells.
The antibody-drug conjugate delivers the cytotoxic payload DM1 specifically to cancer cells.
Tumor-activated prodrug technology enhances targeted cell killing.

Conclusions:

huN901-DM1 represents a targeted therapeutic strategy for CD56-positive malignancies.
This approach holds promise for the treatment of small-cell lung cancer.
Further clinical investigation is warranted to establish the safety and efficacy of huN901-DM1.